Vaccine development CRO Contract Research Organization Wageningen Bioveterinary Research

Vaccine development

The use of vaccines is still the most effective and powerful option in the prevention of animal and human diseases. As a contract research organization (CRO), Wageningen Bioveterinary Research (WBVR) develops vaccines against viral and bacterial diseases together with our public and private clients.

Successful vaccine development

We have extensive experience in the field of vaccine development. In the past, we developed a number of very successful vaccines, e.g. against Aujeszky disease and infectious bovine rhinotracheitis virus.

Due to the broad multidisciplinary expertise on pathogens as well as animal species that are available within WBVR, we can support our clients in the complete process of vaccine development from antigen discovery to registration studies.

Continue to

We will guide you through the process

We invest in the development of vaccine platforms that allow fast and efficient vaccine development for emerging or re-emerging diseases. To guarantee an optimized production of (attenuated) intracellular pathogens, we offer services in cell line development to increase pathogen yield.

Once a putative vaccine is available, we can guide clients through the process of vaccine testing and, if required, Good Clinical Practice standards can be followed. We can perform potency tests and extraneous agent testing according to the European Pharmacopoeia guidelines. WBVR has a full AAALAC accreditation.

- Unfortunately, your cookie settings do not allow videos to be displayed. - check your settings

Vaccinated versus naturally infected animals

Diagnostics are vitally important for disease control of notifiable, infectious diseases. Import and export of animals and animal products is mainly based on serological responses to pathogens.

Vaccination could interfere with this type of diagnostics. Therefore, we developed so-called DIVA vaccines. DIVA vaccines guarantee that vaccinated animals can be discriminated from naturally infected animals. Therefore, vaccine development at WBVR is often combined with the development of discriminative diagnostics.